<i>Letter to the Editor:</i> Tumor Lysis Syndrome During Selpercatinib Treatment in a Patient with Medullary Thyroid Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Letter to the Editor: Tumor Lysis Syndrome During Selpercatinib Treatment in a Patient with Medullary Thyroid Cancer

Published:2023-08-10 Issue: Volume: Page:
ISSN:1050-7256
Container-title:Thyroid®
language:en
Short-container-title:Thyroid®

Author:

De Leo Simone¹,Trevisan Matteo²,Re Sartò Giulia Vanessa³,Moneta Claudia²,Pirovano Marta³,Colombo Carla¹⁴,Cosmai Laura³,Fugazzola Laura¹⁴

Affiliation:

1. Department of Endocrine and Metabolic Diseases, Endocrine Oncology Unit, IRCCS Istituto Auxologico Italiano, Milan, Italy.

2. Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy.

3. Division of Nephrology and Dialysis, ASST Fatebenefratelli-Sacco, Fatebenefratelli Hospital, Milan, Italy.

4. Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.

Publisher

Mary Ann Liebert Inc

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.liebertpub.com/doi/pdf/10.1089/thy.2023.0214

Reference6 articles.

1. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers

2. Neoadjuvant Selective RET Inhibitor for Medullary Thyroid Cancer: A Case Series

3. Tumour lysis syndrome: new therapeutic strategies and classification

4. Acute Kidney Injury in the Patient with Cancer

5. Acute Kidney Injury in Critically Ill Patients with Cancer

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP